Development pipeline
Cytosomatic Labs is a preclinical research organization. This page states where each programme actually sits, what work is underway, and the evidence required to advance — including the phases we have not reached.
Pipeline tracking
Progression runs left to right, from discovery through translational readiness. A bar stops at the last phase whose gate condition is documented.
| Programme | P0 | P1 | P2 | P3 | P4 |
|---|---|---|---|---|---|
| Neural cell therapyEngineered neural and neuroimmune constructs | Reached Assay development — Assay development | ||||
| NeurodiagnosticsMulti-parameter cytometry and transcriptional panels | Reached Assay development — Assay development | ||||
| NeurorestorationFunctional recovery in ex vivo neural models | Reached Discovery — Discovery |
A programme only advances when its gate condition is documented. No phase is skipped, and no phase is described as complete before its record supports it.
Define the mechanism a programme is meant to correct, in human tissue, before any construct is designed.
Gate to advance: A written mechanism hypothesis with a measurable readout and a named failure condition.
Build the measurement before the intervention, so a result cannot be an artefact of the method.
Gate to advance: Assay reproducibility documented across operators, runs and donor material.
Compare engineered neural cell-therapy constructs and delivery chemistries head to head in primary human cells.
Gate to advance: A lead construct with a reproducible mechanistic effect and a characterised safety profile.
Show restored neural function — not restored cell counts — in ex vivo and co-culture models.
Gate to advance: Functional recovery sustained beyond the acute window, with risk modelling attached.
Prepare IND-enabling study design with external clinical and regulatory review.
Gate to advance: External advisory sign-off. No clinical activity occurs before this gate is cleared.
All programmes described here are preclinical. Cytosomatic Labs does not treat patients, run clinical trials, sell products or provide medical advice. Nothing on this page should be interpreted as a claim of clinical efficacy or safety in humans.
Academic groups, clinical investigators and translational funds can request the underlying method records for any active phase.
